ID
22333
Description
A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1 This form is to be completed in Screening Period 1 and after 12 Months +/- 1 week.
Lien
https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1
Mots-clés
Versions (2)
- 22/05/2017 22/05/2017 -
- 30/05/2017 30/05/2017 -
Téléchargé le
30 mai 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Serum HCG Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
Serum HCG Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
Similar models
Serum HCG Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
C2348235 (UMLS CUI [1,2])
C3146298 (UMLS CUI [1,2])
C0430060 (UMLS CUI [2,1])
C0011008 (UMLS CUI [2,2])
C0430060 (UMLS CUI [3,1])
C0040223 (UMLS CUI [3,2])
Aucun commentaire